Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Extracellular vesicles can cross the blood–brain barrier (BBB), but little is known about passage. Here, we used multiple-time regression analysis to examine the ability of 10 exosome populations derived from mouse, human, cancerous, and non-cancerous cell lines to cross the BBB. All crossed the BBB, but rates varied over 10-fold. Lipopolysaccharide (LPS), an activator of the innate immune system, enhanced uptake independently of BBB disruption for six exosomes and decreased uptake for one. Wheatgerm agglutinin (WGA) modulated transport of five exosome populations, suggesting passage by adsorptive transcytosis. Mannose 6-phosphate inhibited uptake of J774A.1, demonstrating that its BBB transporter is the mannose 6-phosphate receptor. Uptake rates, patterns, and effects of LPS or WGA were not predicted by exosome source (mouse vs. human) or cancer status of the cell lines. The cell surface proteins CD46, AVβ6, AVβ3, and ICAM-1 were variably expressed but not predictive of transport rate nor responses to LPS or WGA. A brain-to-blood efflux mechanism variably affected CNS retention and explains how CNS-derived exosomes enter blood. In summary, all exosomes tested here readily crossed the BBB, but at varying rates and by a variety of vesicular-mediated mechanisms involving specific transporters, adsorptive transcytosis, and a brain-to-blood efflux system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 On-bead flow cytometry of exosome populations isolated from supernatants of 4 different cell lines, captured on streptavidin beads coated with biotinylated anti-CD63 mAbs and stained with the labeled detection Abs specific for CD46, αVβ6, αVβ3 and ICAM1 as described in Methods. Data are relative fluorescence intensity (RFI) values calculated as mean fluorescence intensity (MFI) of an experimental sample/MFI of an isotype control Ab. [White peaks = experimental samples; hatched peaks = isotope controls]. Note that exosomes produced by non-malignant cells (HaCaT and primary T cells) appear to differ from exosomes produced by malignant cells by the absence of αVβ3 and lower expression levels of αVβ6. Representative results are from 1 to 3 detection experiments performed with each exosome population.](https://figures.cochat.ai/paper-figures/624d7ee716904379955ce30fbf39b5dc/transport-of-extracellular-vesicles-across-the-blood-brain-barrier-brain-figure-2.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, EVs have inherent targeting capabilities and can cross the BBB, facilitating efficient delivery of therapeutic cargo to the CNS [54–57].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Brain-derived EVs have been found to harbor the ability to penetrate the BBB. This breakdown is crucial as it potentially allows for releasing these EVs into peripheral circulation [54–57].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“sEVs can cross the blood–brain barrier and deliver cargo with crucial roles in many neurological disorders [17–23].”
From Differential RNA packaging into small extracellular vesicles by neurons and astrocytes (2021) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 3×
“EVs we refer to as “exosomes” were isolated by mini-size exclusion chromatography (SEC) from supernatants of 10 different human or murine cell lines (Table 1) and characterized according to the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) criteria [2], as is routinely done in our laborato…”
BackgroundMethodShedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369 · cited 2×
“of parent cells, where they are formed by inverse membrane invagination as intraluminal vesicles inside multivesicular bodies (MVBs) [4].”
BackgroundExtracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 1×
“Exosomes are a subset of small extracellular vesicles (EVs) that are produced by all normal and malignant cells and are present in all body fluids [1].”
BackgroundGraphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Exosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009 · cited 1×
“, drug-loaded exosomes enter the brain using the same mechanisms as those employed by the parent cells [12].”
BackgroundAbels, E. R., & Breakefield, X. O. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0366-z · Cited by 1,678 · cited 1×
“Among the various EVs, exosomes are sized at 30–150 nm in diameter and are of special interest because of their origin, their ability to freely circulate and infiltrate various tissues and their molecular content mirroring that of parental cells [3].”
BackgroundZhang, H., Freitas, D., Kim, H. S., Fabijanic, K., Li, Z., Chen, H., Mark, M. T., Molina, H., Martin, A. B., Bojmar, L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0040-4 · Cited by 1,613 · cited 1×
“The orientation of surface proteins in exosome membranes resembles that in the cell membrane of parent cells [5].”
BackgroundExtracellular Vesicles: Unique Intercellular Delivery Vehicles
Maas, S. L. N., Breakefield, X. O., & Weaver, A. M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.003 · Cited by 1,429 · cited 2×
“Exosomes serve as an intercellular communication system, shuttling messages between cells and also conveying peptides, proteins, and genetic materials from parental to recipient cells [6].”
BackgroundFrom blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Self-citationPlasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Self-citation
Research works printed but not linked: 1
- Nicolini, M., and Zatta, P.F. (1994). Glycoconjugates and anionic sites in the blood-brain barrier. Glycobiology and the Brain, Pergamon Press.
Cited by
Items 501–569 of 569
D’Ambrosio, A., Zamboni, S., Camerini, S., Casella, M., Sanchez, M., Pietraforte, D., Vanacore, N., Diociauti, M., Altieri, M., Piero, V. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26945340
Togre, N. S., Mekala, N. K., Bhoj, P. S., Mogadala, N., Winfield, M., Trivedi, J., Grove, D., Kotnala, S., Rom, S., Sriram, U., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27129354
D’Ambrosio, A., Zamboni, S., Camerini, S., Casella, M., Sanchez, M., Pietraforte, D., Vanacore, N., Diociauti, M., Altieri, M., Piero, V. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26945325
R, A. B., Reddy, K. S., Chandran, D., Hegde, S., Upadhya, R., Kumar, S. E. P., Shenoy, S., Devi, V., & Upadhya, D. (2024) · Figshare · doi:10.6084/m9.figshare.25649344
Togre, N. S., Mekala, N. K., Bhoj, P. S., Mogadala, N., Winfield, M., Trivedi, J., Grove, D., Kotnala, S., Rom, S., Sriram, U., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27129330
Togre, N. S., Mekala, N. K., Bhoj, P. S., Mogadala, N., Winfield, M., Trivedi, J., Grove, D., Kotnala, S., Rom, S., Sriram, U., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27129351
Togre, N. S., Mekala, N. K., Bhoj, P. S., Mogadala, N., Winfield, M., Trivedi, J., Grove, D., Kotnala, S., Rom, S., Sriram, U., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27129339
D’Ambrosio, A., Zamboni, S., Camerini, S., Casella, M., Sanchez, M., Pietraforte, D., Vanacore, N., Diociauti, M., Altieri, M., Piero, V. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26945349
Togre, N. S., Mekala, N. K., Bhoj, P. S., Mogadala, N., Winfield, M., Trivedi, J., Grove, D., Kotnala, S., Rom, S., Sriram, U., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27129333
D’Ambrosio, A., Zamboni, S., Camerini, S., Casella, M., Sanchez, M., Pietraforte, D., Vanacore, N., Diociauti, M., Altieri, M., Piero, V. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26945334
Developing High-Yield and Safe Therapeutic EVs by Ablating Tissue Factor-Mediated ToxicityPreprint
Luo, Q., Li, X., Yang, M., Li, X., Xu, S., Jiang, T., Xia, J., Ding, J., Qin, X., & Zhao, T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.25.696171
“While inflammation can increase CNS uptake [ 26 , 27 ], under normal conditions less than 1% of injected EVs cross the blood–brain barrier [ 28 , 29 ].”
Crosstalk of Tumor-Derived Extracellular Vesicles with Immune Recipient Cells and Cancer Metastasis
Jie, H., Głuszko, A., & Whiteside, T. L. (2026) · Cancers · doi:10.3390/cancers18020196
“Upon their release by the tumor cells into intercellular space, TEX migrate, enter the vascular and lymphatic systems and circulate freely reaching all tissues and all body fluids [8–10].”
Self-citationHazzard, H., Blaine, B., Borrman, B. B., Shen, S. Q., & Gumusoglu, S. B. (2026) · Current Opinion in Physiology · doi:10.1016/j.cophys.2026.100913 · Cited by 5
Bennett, A. P. S. (2026) · Open Research Europe · doi:10.12688/openreseurope.22603.1
Li, Y., Sun, C., & Liu, Q. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2025-0007 · Cited by 1
Peri-implantitis derived extracellular vesicle as vectors of neuroinflammation
Tessarin, G. W. L., dos Santos, R. M., & Toro, L. F. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1773682
Investigation of miRNAs affecting schwann cells in patients with trigeminal neuralgia
Onrat, S. T., Issı, E. S., Gönen, H. N., Acar, H., & Börü, Ü. T. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11636-x
“Therefore, circulating miRNA levels may partially reflect central nervous system (CNS)-derived molecular signals in addition to peripheral sources [35 ].”
Identification of a miRNA signature for schizophrenia in plasma-derived extracellular vesiclesPreprint
Collier, M. E. W., Chiappelli, J., Marshall, H., Sylvius, N. B., Allcock, N., Whittingham, J., Kochunov, P., Schwarcz, R. M., Hong, E. L., & Giorgini, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.06.710021
Black carbon is detectable in association with small extracellular vesicles in fetal circulation
Kahroba, H., Vanbrabant, K., Krauskopf, J., Briedé, J. J., Ameloot, M. M., Plusquin, M., Roeffaers, M. B. J., de Kok, T. M. C. M., & Nawrot, T. (2026) · Environment International · doi:10.1016/j.envint.2026.110186
Cui, L., Ono, F., Ichinose, T., Goto, M., & Ishihama, K. (2026) · Journal of Extracellular Biology · doi:10.1002/jex2.70125 · Cited by 1
Physiological strategies for brain delivery
Carter, D. A. G. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.02.007
Commentary: RNA transcripts in salivary extracellular vesicle cargo isolated from aged populations
Yin, L. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1799802
“Banks et al. demonstrated that EVs can traverse the blood-brain barrier (BBB) via specific transport mechanisms, with inflammatory states modulating their kinetics (Banks et al., 2020).”
Exosomes as cellular couriers: the mechanisms of intercellular messaging
Reddy, M. M. S., Srivastava, A. K., & Prabhakaran, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36390-0.00009-9
Crossing the blood–brain barrier: exosomes in neurological research
Prakāsh, C., Saran, S., & Sharma, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36390-0.00019-1
Koley, R., De, S., Ghosh, A., Bhattacharjee, D., Mitra, A., Mondal, B., Pahari, A., Nandi, M., Kanri, R., Dasgupta, S., et al. (2026) · In vitro models · doi:10.1007/s44164-026-00111-3
Exosome Bioprocessing toward Medical, Pharmaceutical, and Cosmetic Application
Kim, T. H., & Hong, J. W. (2026) · KSBB Journal · doi:10.7841/ksbbj.2026.41.1.34
Gene and Cell Technologies for Treatment of Brain Malignancies
Abdrakhmanova, I. I., Kitaeva, K. V., Gorodilova, A. V., Saidgaraeva, M. G., Rizvanov, A. A., & Solovyeva, V. V. (2026) · Molecular Biology · doi:10.1134/s0026893325700633
Revisiting an immunoneuropsychiatry classic: Sydenham’s chorea
Teixeira, A. L., Maia, D. P., Nunes, M. C. P., de Erausquin, G. A., Zeni, C. P., & de Miranda, A. S. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2660763
“Recently, a growing body of evidence has highlighted the potential pathogenic role of extracellular vesicles (EVs) that can cross the BBB and deliver pathogenic cargo into the brain, including the basal ganglia [52–54].”
Drug loading techniques for extracellular vesicles for biomedical applications
Chaudhary, U., Rana, D., Benival, D. M., & Garkhal, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36641-3.00003-6
Engineered Exosomes: Innovative Strategies for Precision Drug Delivery in Parkinson’s Disease
Yuan, X., Wang, C., Yan, J., Wang, J., Li, F., You, Y., & Qi, Z. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05898-6
“These characteristics markedly enhance the bioavailability of encapsulated therapeutics, positioning exosomes as ideal vehicles for neurorestorative and disease-modifying approaches in PD [75, 76].”
Engineered neuronal exosomes mediate α-synuclein clearance to ameliorate Parkinson’s disease
Chen, L., Lin, X., Fu, M., Chen, S., Yan, Z., Diao, Y., Chen, G., Huang, Z., Sun, Y., Lin, Y. Y., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04552-6
“…that specific proteins on the exosome membrane surface (e.g., tetraspanins and integrins) can interact with endothelial cell receptors and deliver cargo into the brain through receptor-mediated transcytosis [57–59], providing a theoretical basis for the brain-targeted delivery of EL@ sPep/P.”
Repurposing the skin to heal the body: Tissue Nanotransfection (TNT) as a therapeutic platform
Salazar‐Puerta, A. I., Stanford, K., Higuita‐Castro, N., & Gallego‐Perez, D. (2026) · Med-X · doi:10.1007/s44258-026-00084-8 · Cited by 2
Togre, N. S., Carpio‐Cano, F. D., Mekala, N. K., Winfield, M., Sriram, U., Rom, S., & Persidsky, Y. (2026) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2026-0013
“Importantly EVs can carry inflammatory cargo (e.g., cytokines, nucleic acids) and traverse endothelial tissue barriers [55, 56] that can potentially contribute to intercellular communication and inflammatory processes across organs [44, 57, 58].”
Extracellular vesicles MicroRNAs in stroke therapy: recent advances and translational potential
Ding, Y., Ma, Y., Hu, J., Wei, M., Liao, H., Yang, Y., Gu, J., & Tan, R. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.06.008 · Cited by 3
Deng, L., Li, H., Yang, S., Chen, F., Qiao, J., 包慧中, Wang, X., Fang, S., Xu, B., & Tang, Z. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04654-1
“Exosomes can facilitate brain-targeted delivery in CNS disorders through surface-associated molecules that mediate multiple BBB transport pathways [221].”
Li, Q., Xu, J., Zhang, Y., Qian, J., Ong, D. B., Mun, K. S., Tang, Y. H., Geng, X., & Phang, K. C. (2026) · Biomolecules · doi:10.3390/biom16060906 · Cited by 1
“Furthermore, building upon these mechanisms, future translational endeavors could explore surface-engineering technologies to maximize active BBB penetration, ensuring precise therapeutic targeting of this circRNA network in GBM [57–61].”
Ellis, R. J., Tang, B., Riggs, P. K., Ludicello, J., Marcondes, M. C. G., Delorme, V., Heaton, R. K., & Letendre, S. L. (2026) · Scientific Reports · doi:10.1038/s41598-026-59301-4
Salivary Extracellular Vesicles: Paradigm Shift in Liquid Biopsy Diagnostics
Xulu, K., Ibrahim, U. H., Mackraj, I., & Niesler, C. U. (2026) · Journal of Extracellular Biology · doi:10.1002/jex2.70166 · Cited by 2
“…EVs gain access to multiple biofluids through various mechanisms (Iannotta et al. 2024 ) and have been reported to cross the blood-brain-barrier (Banks et al. 2020 ; Ramos-Zaldívar et al. 2022 ), extending their reach to compartments traditionally considered inaccessible to other circulating…”
Extracellular Vesicles in Stroke: Drivers of Brain–Body Network Crosstalk
Xu, Z. Y., Yu-Jia, J., Zhang, W., Ye, X.-H., & Gao, F. (2026) · Translational Stroke Research · doi:10.1007/s12975-026-01452-7
“2) How EV-associated signals interface with the CNS depends in part on blood–brain barrier (BBB) state [14].”
InfluentialPourvali, M., Abroushan, D., Durosini, E., Al-Musawi, S., & Sheykhhasan, M. (2026) · Molecular and translational medicine · doi:10.1007/978-3-032-23810-8_10
Lin, S. J., Lan, R., Zhu, X., Shen, R., Liu, R., Cheng, J., & Liu, X. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080945
“In pathological conditions such as inflammation, increased endothelial permeability further promotes the exchange of exosomes between tissues and circulation [94].”
Wang, L., Luo, L., Zhang, Z., Li, X., Xu, Y., Luo, H., Lyu, Q., & Shang, F. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00851-0
“…is a specialized extracellular matrix rather than an absolute barrier; accumulating evidence suggests that EVs can traverse the extracellular matrix and mediate intercellular communication, supporting the feasibility of EV-mediated signaling between endothelial cells and astrocytes [22, 23].”
Exosomes in brain diseases: Mechanisms, advances, and perspectives
Cheng, Q., Zhu, Y., Lv, S., Chen, R., Liu, P., & Ji, X. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.07.055 · Cited by 1
“Similarly, Banks et al. systematically evaluated the BBB permeability of exosomes derived from multiple malignant and non-malignant cell sources using mouse models and demonstrated that exosome brain uptake varies depending on vesicle origin and biological properties [59].”
Zhao, Q., Liu, T., Xing, J., Kong, Z., Hu, D., Xia, M., Li, H., Chen, Z., Fei, L., Wang, X., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-26-00586
Jin, W., Chen, S., Li, D., Chen, Q., Wang, M., Fu, X., Qu, C., & Ping, L. (2026) · iScience · doi:10.1016/j.isci.2026.117224
“3 This is a narrative review of the human evidence on EV-based biomarkers in MDD. 6 Despite extensive investigation, none has achieved regulatory approval or routine clinical adoption.”
InfluentialGuo, H., Savard, A., Manser, C., Dutta, K., Taylor, J. A., Rousseaux, M. W. C., Pozzi, S., Julien, J., Baird, S. D., & Gibbings, D. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01774-9 · Cited by 1
Matrix-bound extracellular vesicles
Celebi, L. E., Hawthorne, L., Higuita‐Castro, N., Gallego‐Perez, D., He, M., Vader, P., Manickam, D. S., Eniola‐Adefeso, L., Cheng, K., & Zorlutuna, P. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00477-9 · Cited by 1
“Therefore, matrixbound and liquidphase EVs may have distinct thera peutic utilities, underscoring the importance of studying them both separately and in combination to define their potentially synergistic effects.”
Sewell, P. E., & Jensen, C. (2026) · Frontiers in Drug Delivery · doi:10.3389/fddev.2026.1906950
Widłak, P., Han, J., Głuszko, A., Mika, J., Zebrowska, A., Mondal, S. K., Gawin, M., Najjar, Y. G., Polańska, J., Pietrowska, M., et al. (2026) · European Journal of Immunology · doi:10.1002/eji.70273
Self-citationMahajan, S., Morais, R. A., Chavan, R., Martins, G. A. D. S., Pawase, P. A., Bashir, O., & Abdi, G. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107500 · Cited by 1
Elliott, B. B., Prasad, V. V., Taylor, A., Shofner, I., Kerns, K. C., Meyer, J., & McNeill, E. M. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1910088
“EVs are lipid bilayer-enclosed nanoparticles that carry cargo, including miRNAs, and can cross the blood-brain barrier (Banks et al., 2020; Kumar et al., 2024), enabling systemic transport of miRNAs (Iannotta et al., 2024).”
Korkutata, M., & Dilsiz, N. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06175-2
“Exosomes hold great promise for treating neurological disorders; for example, bone marrow–derived MSC-Exos have shown therapeutic effects in a rat model of PD [214, 215].”
Wei, X., Liu, F., Yao, J., Feng, P., Xue, F., & Shi, Z. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06224-w
“…N-formyl peptides can also function as mtDAMPs and activate inflammatory responses through pathways involving Toll-like receptor 9 (TLR9), cGAS–STING, the NOD-like receptor protein 3 (NLRP3) inflammasome, purinergic P2X7 receptors, and receptor for advanced glycation end products (RAGE) [88].”
Liu, T., Cao, H., Chen, X., Huang, J., Zhang, Q., Sun, M., Zeng, W., & Su, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930673
“…interest for this review, thanks to their unique lipid-protein composite structure, Exos possess the innate ability to cross the BBB, thereby bypassing it as a drug-delivery barrier and serving as an ideal carrier for targeted drug delivery in IS (Abdelsalam et al., 2023; Banks et al., 2020).”
Luo, Z.-Y., Han, R.-J., Guo, T.-J., Huang, H., Bai-he, S., Xu, J.-L., Zhang, W., Li, J.-Z., Sang, Z., Mei, Z.-T., et al. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100674
“As endogenous nanoscale vesicular carriers, EVs have demonstrated inherent potential to penetrate the BBB and distribute within the CNS (Banks et al., 2020), remain stable in vivo for more than 48 h (Gu et al., 2022), and can be engineered with targeting moieties to precisely deliver therapeutic payloads to sites of i…”
InfluentialMekala, N. K., Togre, N. S., Kurian, S., Rom, S., Sriram, U., & Persidsky, Y. (2026) · Cells · doi:10.3390/cells15191750
“EV-mediated delivery facilitates the transfer of these proteins to endothelial cells, including those of the BBB [27].”
Williams, J. O., Raven, R. M., Whelan, C., Toms, R., Crabtree, M., Morris, K., White, J., Geen, J., & James, P. E. (2026) · Journal of Stroke Medicine · doi:10.1177/25166085261478705
Mohtashami, T., Atashi, A., Khaksari, M., & Garmabi, B. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115513
Bi, X., Gootin, H., Su, W., & Baudry, M. (2026) · Bioengineering · doi:10.3390/bioengineering13101140
“…cell-derived EVs influence blood–brain barrier (BBB) integrity, vascular remodeling, and neurovascular coupling, while brain-derived EVs can traverse the BBB and mediate bidirectional communication between the CNS and peripheral organs under both physiological and pathological conditions [87–89].”
Azhar, M., Malviya, R., Vandana, Chandra, P., Sridhar, S. B., Shareef, J., Wadhwa, T., & Arockiam, D. (2026) · ASN NEURO · doi:10.1080/17590914.2026.2736964
“Hence, the shared molecular pathways should not be interpreted as evidence of a confirmed EV-mediated causal pathway, but rather as a biologically plausible interface (Almarhoumi et al., 2023; Alvarenga et al., 2021; Banks et al., 2020; Mansouri et al., 2025).”
Advances in Extracellular Vesicle–Based Innovative Drugs Targeting Alzheimer’s Disease
Liu, S., Lu, J., Liu, J., Liu, H., Liu, Z., Danjing, Y., Liang, X., & Xu, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06223-x
“…) in an The development of EV-based therapies for AD is essentially leveraging the natural delivery mechanisms of EVs to solve two major historical challenges in neurology: the inability of traditional drugs to effectively enter the brain [10] and the limitation of single-target approaches (Fig.”
Emerging roles of migrasomes in blood–tissue barrier integrity and intercellular signaling
El-Sheikh, A. A., & Aldahhan, R. A. (2026) · Tissue Barriers · doi:10.1080/21688370.2026.2738431
La, Y., Yuan, J., Chen, J., Lv, K., Wang, X., qiqi, G., Wang, Y., Wang, C., Xu, B., Yang, Y., et al. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00588-8
“In mice, systemically administered extracellular vesicles can cross the intact blood–brain barrier, although their rates of brain entry vary according to vesicle origin and can be altered by systemic inflammation [104].”
Park, G., Yoo, H.-R., & Lim, H.-S. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00608-z
Cai, S., Hu, Z., Ma, X., & Sheng, J. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2026.94
Lin, L., Patil, M., Hawke, S. H., Marsh‐Wakefield, F., & Grau, G. E. (2026) · Microcirculation · doi:10.1111/micc.70091
Lu, W., Yan, J., & Feng, H. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71211
“…endothelial binding, adsorptive or receptor-mediated uptake/transcytosis, and inflammation-dependent changes in barrier permeability; however, CNS penetration should not be assumed as a class effect and requires quantitative, product-specific biodistribution and dose– response assessment [52].”
The Roles and Uses of Extracellular Vesicles in Neuroimmunologic Diseases
Kammeyer, R., & Coughlan, C. M. (2026) · Journal of Neuroscience · doi:10.1523/jneurosci.2310-25.2026
Metadata
- Authors
- Banks, W. A., Sharma, P., Bullock, K. M., Hansen, K. M., Ludwig, N., & Whiteside, T. L.
- Affiliations
- University of Washington (US)
- University of Pittsburgh (US)
- Corresponding author
- Banks, William A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-21
- Volume
- 21
- Issue
- 12
- Pages
- 4407
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352415
- OpenAlex
- W3036596408
- Cited by
- 561
- References
- 57
- Citations by year
- 2026: 99 · 2025: 102 · 2024: 132 · 2023: 90 · 2022: 81 · 2021: 54 · 2020: 2
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health (1RO1 AG046619)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- extracellular vesicles, exosomes, blood-brain barrier, BBB crossing, brain pharmacokinetics, lipopolysaccharide, inflammation, mannose 6-phosphate receptor, CD46, integrins, ICAM-1, vesicular transporters
- MeSH terms
- Animals, Biological Transport, Blood-Brain Barrier, Cell Line, Humans, Inflammation, Male, Cell Line, Tumor, Mice, Exosomes, Transcytosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.